ArticleJournal of ultrasound2026
Follow-up study of the cardiac manifestations of multiethnic patients hospitalised with COVID-19.
Article in Journal of ultrasound, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine the natural history of the cardiac manifestations, determined by advanced transthoracic echocardiography (TTE), due to COVID-19 in multiethnic hospitalised patients.
methodsA prospective observational study, in a London NHS Trust, of patients admitted with COVID-19 undergoing TTE. Baseline TTE was taken during acute admission with follow-up TTE at a median of 17.6 months to assess the same left ventricular (LV), right ventricular (RV) and pulmonary pressure parameters with additional 3D and strain measures.
resultsThere were a total of 117 patients with admission and follow-up TTE. LV parameters were largely unchanged at follow-up except E/A ratio decreasing from 0.98 to 0.85. LV global longitudinal strain measures detected subclinical LV impairment in 36% of patients. RV dimensions improved (mean mid RV diameter, 3.1 cm to 2.7 cm (p < 0.001)) but with persistence of RV impairment at follow-up (28%). 3D RV ejection fraction and global strain measures determined impairment in around 40% of patients. All pulmonary haemodynamic measures showed improvement with resolution of effects of RV afterload (p = 0.016), decrease in pulmonary artery systolic pressure (36 mmHg to 28 mmHg p = 0.032) and improvements in mean pulmonary valve acceleration time (113 ms to 120 ms), p = 0.025, and pulmonary vascular resistance (2.2 to 1.7 WU), p = 0.01.
conclusionFollow-up echocardiographic parameters compared to admission parameters of multiethnic hospitalised patients with COVID-19 demonstrate improved pulmonary haemodynamics but persistent LV and RV impairment which suggest possible myocarditic/microthrombotic lasting effects of COVID-19 infection.
Indexed as
Identifiers
42533273What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.